ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0496

Giant Cell Arteritis Relapse Risk – Could the Extent of Vessel Involvement on Temporal and Axillary Arteries Ultrasound Be a Prognostic Marker?

Diogo Esperança Almeida1, Kate Smith2, Borsha Sarker2, Andrew Barr3, Richard Wakefield4 and Sarah Mackie4, 1Serviço de Reumatologia, Hospital de Braga, Braga, Portugal, Braga, Portugal, 2National Institute for Health and Care Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom; 4. Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom; National Institute for Health and Care Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom

Meeting: ACR Convergence 2022

Keywords: giant cell arteritis, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: To determine if disease extent on ultrasound (US) of temporal and axillary arteries predicts a relapsing course of giant cell arteritis (GCA).

Methods: We conducted a single-centre retrospective study in which consecutive patients diagnosed with GCA between January 2019 (beginning of GCA fast-track US evaluations in the department) and May 2021 records were reviewed. Using Cox proportional hazards regression, we evaluated if disease extent, defined as the number of vessels showing non-compressible halo – ‘halo count’ – on baseline US scan performed as part of the diagnostic work-up is able to predict the risk of relapse in GCA.

Results: A total of 72 patients with a clinical diagnosis of GCA in which an US scan was performed in the diagnostic work-up were included. Thirty-seven (51.4%) experienced a relapse of GCA (median follow-up of 20.9 months; median time-to-first relapse of 6.3 months), ultimately needing treatment escalation. In a multivariable Cox regression model (n=72; -2 log likelihood = 275.63; chi-square = 8.03; df = 3; P = 0.045), halo count was found to be a significant predictor of time-to-relapse in GCA (HR = 1.19; CI 95% 1.04, 1.35; P = 0.012) after adjustment for patient sex and presence of ischaemic symptoms.

Conclusion: GCA disease extent as defined by US halo count at the time of diagnosis may predict relapsing disease and may help clinicians stratify care for these patients. Larger prospective studies are needed to confirm our findings.


Disclosures: D. Esperança Almeida, None; K. Smith, None; B. Sarker, None; A. Barr, None; R. Wakefield, Galapagos, Jansson; S. Mackie, Roche/Chugai, Pfizer (speaker on behalf of my institution - no personal fees received), AbbVie - Consultancy on behalf of my institution (no personal fees received), AstraZeneca - Consultancy on behalf of my institution - no personal fees received, Roche/Sanofi - work on behalf of my institution (no personal fees received), Vifor - on behalf of my institution (no personal fees received).

To cite this abstract in AMA style:

Esperança Almeida D, Smith K, Sarker B, Barr A, Wakefield R, Mackie S. Giant Cell Arteritis Relapse Risk – Could the Extent of Vessel Involvement on Temporal and Axillary Arteries Ultrasound Be a Prognostic Marker? [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/giant-cell-arteritis-relapse-risk-could-the-extent-of-vessel-involvement-on-temporal-and-axillary-arteries-ultrasound-be-a-prognostic-marker/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/giant-cell-arteritis-relapse-risk-could-the-extent-of-vessel-involvement-on-temporal-and-axillary-arteries-ultrasound-be-a-prognostic-marker/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology